Title: MCM6 is a Poor Prognostic Biomarker and Promotes Progression in Breast Cancer
Authors: Zi Lei, Peng Wang, Da-qi Jia, Lei-lei Li, Yi-peng Wu, Yuan Yang, Guo-qing Pan, Taeg Kyu Kwon
Section: 3.6 MCM6 Knockdown Inhibited the Proliferation of Breast Cancer Cells
Innovation team of Education Department of Yunnan Province (K1322121), and High-level personnel training program of Yunnan Province (RLMY20200016). Conflict of Interest The authors declare no conflict of interest. References [1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 2022; 72: 7–33. [2] Lukong KE. Understanding breast cancer - The long and wind- ing road. BBA Clinical. 2017; 7: 64–77. [3] Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast can- cer intrinsic subtype classification, clinical use and future trends. American Journal of Cancer Research. 2015; 5: 2929–2943. [4] de Melo Gagliato D, Jardim DLF, Marchesi MSP, Hortobagyi GN. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget. 2016; 7: 64431– 64446. [5] OhDY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nature Reviews. Clinical Oncology. 2020; 17: 33–48. [6] Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triplenegative breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013; 31: 2586–2592. [7] Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2009; 15: 7381– 7388. [8] Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007; 12: 395–402. [9] Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108: 3761–3766. [10] Rizzo A, Ricci AD. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opinion on Investigational Drugs. 2022; 31: 549–555. [11] Viscardi G, Tralongo AC, Massari F, Lambertini M, Mollica V, Rizzo A, et al. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combinationwith other agents across solid malignancies: a systematic review and meta-analysis. European Journal of Cancer (Oxford, England: 1990). 2022; 177: 175–185. [12] Rizzo A, Cusmai A, Acquafredda S, Rinaldi L, Palmiotti G. Ladiratuzumab vedotin for metastatic triple negative